In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates

Abstract

These findings suggest that monotherapy with colistin methanesulphonate, the parenteral form of colistin, and long dosage intervals (e.g. 24 h) may be problematic for treatment of infections caused by colistin heteroresistant A. baumannii.